SFL’s CEO Shayesteh Fürst-Ladani presented at the webinar hosted by the Swiss Business Hub United Kingdom & Ireland on ‘How executives can enhance their IP strategy and performance in Switzerland’. She shared regulatory and market access perspectives for medicines in Switzerland with attendees and underlined that “the Swiss law offers data protection and SPC extension for innovative medicines and numerous multilateral agreements with global regulatory authorities accelerate approval of medicines in Switzerland significantly”.

SFL’s multi-disciplinary team can provide customized strategic advice and act as MAA and MAH in Switzerland. SFL services cover the entire lifecycle of health care products and our team has extensive expertise for medicines, medical devices and combination products.